EyeGate receives FDA approval to initiate PRK pivotal study
By Akshay Kedari  Date: 2019-06-04

EyeGate receives FDA approval to initiate PRK pivotal study

EyeGate Pharmaceuticals, Inc. has reportedly received approval from the U.S. Food and Drug Administration to start photorefractive keratectomy or PRK pivotal study.

As per trusted sources, the FDA has determined that EyeGate provided adequate data to support the initiation of the clinical study and has asked the pharma company to make some alterations in the patient informed consent document before enrollment. Sources claim that the company will immediately address these changes and looks forward to enrollments starting this month.

Sources familiar with the knowledge of the matter cite Stephen From, Chief Executive Officer of EyeGate, to have said in a statement that the company is extremely pleased with the comments received from the FDA about the design of the company’s PRK pivotal study and plans to initiate enrollment at the earliest.

The company expects topline outcomes by the end of 2019, anticipating them to be positive, so that the de novo application for commercialization can be submitted soon, From claimed, adding that post the successful approval, the company’s OGB platform will be the United States’ foremost prescription Hyaluronic Acid eyedrop formulation presenting a huge opportunity for the company.

According to a reliable news report, EyeGate Pharmaceuticals Inc. stock spiked 20% as of June 3. The company’s stock has reportedly climbed $0.05 from the earlier closing price of $0.25 on a volume of 3,160,386 stocks.

For the record, EyeGate is a clinical-stage specialty pharmacological company dedicated to developing and commercializing drugs and therapeutics through its two proprietary platform technologies focused on the treatment of eye diseases and disorders.

The company’s OBG platform formed on a crosslinked thiolated CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that holds unique physical and chemical features such as hydrating and healing properties when applied to the ocular surface, reported sources. 

Source Credit
https://finance.yahoo.com/news/eyegate-receives-approval-fda-initiate-105500530.html

https://www.investorsobserver.com/market-intelligence-center/stock-update/is-eyegate-pharmaceuticals-eyeg-stock-a-strong-buy-following-fda-study-approval/


 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...

Sprout to expand wellness solutions lineup by acquiring Vivametrica
Sprout to expand wellness solutions lineup by acquiring Vivametrica
By Akshay Kedari

Sprout, a Canadian company that focuses on delivering innovative solutions for workplace wellbeing, has recently announced the acquisition of predictive health data analytics firm, Vivametrica. According to reliable sources, Sprout plans to enhance t...

Uber halts decision to shift APAC headquarters from Singapore
Uber halts decision to shift APAC headquarters from Singapore
By Akshay Kedari

Uber Technologies Inc., the American ride-hailing giant, has reportedly halted the company’s decision to relocate its Asia Pacific headquarters from Singapore to Hong Kong until December 2022. Sources cite that the company’s decision was...

PCI Pharma extends global clinical supply-chain services in Europe
PCI Pharma extends global clinical supply-chain services in Europe
By Akshay Kedari

U.S. based biopharmaceutical and pharma outsourcing services company, PCI Pharma services has reportedly announced that it reached a noteworthy milestone through the development of COE (Clinical Center of Excellence) in Berlin. According to credible...